ATTO

Attovia Therapeutics Inc

13.73

Oct 16 • 3:59 PM ET -1.05 (-7.10%)

13.75

Aftermarket • 7:30 PM ET +0.02 (0.15%)

Healthcare Biotechnology USA Small NASD

Peers: BDRX ELOX SCNI BBLG SLXN VBIO GNPX MBRX AZTR CLDI

| Held by: VTI VXF SCHA VTWO SCHB VTWG VTWV VTHR

Scroll to Statements

Index	-
Market Cap	626.79M
Enterprise Value	774.22M
Income	-
Sales	-
Book/sh	-3.19
Cash/sh	2.52
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 05, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	5.44
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.39
Current Ratio	9.39
Debt/Eq	0.04
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.56
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 02 AMC
EPS/Sales Surpr.	-655.81% 42.09%

Insider Own	37.71%
Insider Trans	19.66%
Inst Own	15.65%
Inst Trans	10.48%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-19.64%
SMA50	-30.79%
SMA200	-30.96%
Trades

Shs Outstand	45.65M
Shs Float	28.44M
Short Float	5.80%
Short Ratio	3.67
Short Interest	1.65M
52W High	28.00 -50.96%
52W Low	14.23 -3.52%
Volatility	10.47% 9.11%
ATR (14)	1.67
RSI (14)	27.66
Beta	-
Rel Volume	2.18
Avg Volume	448.90K
Volume	977,910

Perf Week	-15.30%
Perf Month	-39.60%
Perf Quarter	-
Perf Half Y	-
Perf YTD	-34.62%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	42.20
Prev Close	14.78
Price	13.73
Change %	-7.10%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-31-26	Initiated	RBC Capital Mkts	Outperform	$45
Aug-31-26	Initiated	Morgan Stanley	Overweight	$39
Aug-31-26	Initiated	Leerink Partners	Outperform	$52
Aug-31-26	Initiated	Citigroup	Buy	$30

Sep-28-26 04:05PM	Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 (GlobeNewswire)
Sep-22-26 01:39PM	Was Moderna Stock's Cancer Vaccine Run Visible In Advance? (Trefis)
Sep-03-26 04:05PM	Attovia Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.58%
Sep-02-26 04:05PM	Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-31-26 09:45AM	Deere upgraded, Lumentum initiated: Wall Street's top analyst calls (The Fly)
11:13AM	Loading…
Aug-26-26 11:13AM	Moderna Stock Carries A Market Value Its Revenue Does Not Support (Trefis)
Aug-24-26 03:01PM	Moderna Stock Had A Readout Waiting In Plain Sight (Trefis)
Aug-20-26 02:21PM	Moderna's Melanoma Result Landed On A Market Positioned The Other Way (Trefis) -8.72%
Aug-06-26 04:05PM	Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.94%
05:57AM	Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq (PR Newswire)

Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that creates next-generation biologic medicines for immune-mediated diseases. It was founded in 2022 and is headquartered in San Carlos, CA.

M.S.Mr. Tao Fu M.B.A.

Chief Scientific OfficerDr. Petter Veiby Ph.D.

M.P.H.Dr. Hubert C. Chen M.D.

Chief Financial OfficerMr. Steven Chan CPA

Chief Technology OfficerDr. Hangjun Zhan Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOLDMAN SACHS GROUP INC	Former 10% Owner	Aug 05 '26	Proposed Sale	21.00	105,807	2,221,947		Aug 28 05:50 PM
WALSH COLIN	Director	Aug 06 '26	Buy	17.00	500,000	8,500,000	3,020,632	Aug 13 09:52 PM
WALSH COLIN	Director	Aug 05 '26	Buy	21.00	85,000	1,785,000	85,000	Aug 13 09:52 PM
WALSH COLIN	Director	Aug 05 '26	Sale	21.28	105,807	2,251,658	0	Aug 13 09:52 PM
GOLDMAN SACHS GROUP INC	Former 10% Owner	Aug 06 '26	Buy	17.00	500,000	8,500,000	3,020,632	Aug 13 09:51 PM
GOLDMAN SACHS GROUP INC	Former 10% Owner	Aug 05 '26	Buy	21.00	85,000	1,785,000	85,000	Aug 13 09:51 PM
GOLDMAN SACHS GROUP INC	Former 10% Owner	Aug 05 '26	Sale	21.28	105,807	2,251,658	0	Aug 13 09:51 PM
venBio Global Strategic Fund I	10% Owner	Aug 06 '26	Buy	17.00	382,352	6,499,984	4,181,367	Aug 10 04:12 PM
Redmile Group, LLC	10% Owner	Aug 06 '26	Buy	17.00	400,000	6,800,000	1,182,854	Aug 07 09:47 PM
Redmile Group, LLC	10% Owner	Aug 06 '26	Buy	17.00	200,000	3,400,000	982,854	Aug 07 09:47 PM
Sanofi	10% Owner	Aug 06 '26	Buy	17.00	300,000	5,100,000	1,082,855	Aug 07 03:45 PM
Frazier Life Sciences XI, L.P.	10% Owner	Aug 06 '26	Buy	17.00	588,235	9,999,995	6,154,213	Aug 06 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATTO

Attovia Therapeutics Inc

Upgrade your Finviz experience